Ioduro (131i) De Sodio Ge Healthcare

Sodium Iodide (131I), the active ingredient in Ioduro (131i) De Sodio, is a radioactive iodine presented as an oral solution for oral use. It is used in the diagnosis and treatment of thyroid disorders, including imaging, cancer therapy, and hyperthyroidism.

GNH USA supplies Ioduro (131i) De Sodio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ioduro (Sodium Iodide 131I) is employed in the thyroid pathway for both diagnostic and therapeutic purposes.

Thyroid imaging: Enables visualization of thyroid tissue using radioactive uptake for diagnostic scans. Thyroid cancer treatment: Delivers targeted radiation to thyroid carcinoma cells to reduce tumor burden. Hyperthyroidism: Provides therapeutic radiation to suppress overactive thyroid tissue.

Adverse reactions may occur following oral administration of radioactive iodine.

Common Side Effects: - Nausea or vomiting - Altered taste sensation - Mild salivary gland discomfort - Transient fatigue - Temporary hypothyroidism - Mild headache

Serious or Rare Side Effects: - Severe hypothyroidism requiring hormone replacement - Radiation thyroiditis - Bone marrow suppression - Allergic reactions such as rash or anaphylaxis - Radiation‑induced sialadenitis - Rare secondary malignancies

Use of Ioduro requires careful consideration of patient‑specific factors and handling requirements.

Pregnancy: Use only if clearly needed; potential fetal radiation exposure. Breastfeeding: Contraindicated; iodine may be secreted in milk. Renal impairment: Adjust dose; reduced clearance may increase systemic exposure. Thyroid function: Baseline assessment required before administration. Drug interactions: Avoid concurrent high‑iodine substances. Store at ambient temperature: Keep below 25°C, in the original container, protected from moisture and light.

Ioduro may interact with other medications that affect iodine handling or thyroid function.

Major Interactions (Avoid): - Antithyroid drugs (e.g., propylthiouracil, methimazole): May reduce uptake of radioactive iodine. - High‑iodine contrast agents: Can block thyroid uptake of I‑131. - Lithium carbonate: Increases retention of iodine in the thyroid, altering therapeutic effect.

Moderate Interactions (Monitor Closely): - Amiodarone: Contains iodine and may affect dosing. - Corticosteroids: May modify inflammatory response after therapy. - Diuretics: May affect renal clearance of iodine.